LIFE News and Press, aTyr Pharma Inc. From 04/13/22

SAN DIEGO, April 13, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the U.S. Food and Drug Administration (FDA) has ...

The U.S. FDA has granted Orphan Drug Status to aTyr Pharma's (NASDAQ:LIFE) efzofitimod for systemic sclerosis. Share are up 5% in after-hours trading. The condition, also known as scleroderma, is an autoimmune disorder characterized by the chronic hardening and tightening of the ski...

SAN DIEGO, April 11, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced a poster presentation at the 2022 American Association for Cancer ...

Results from Phase 1b/2a study of efzofitimod in pulmonary sarcoidosis patients demonstrate safety and dose dependent trends of improvement compared to placebo for key efficacy endpoints. Efzofitimod treatment reduces pro-inflammatory serum biomarkers in pulmonary sarcoidosis pati...

SAN DIEGO, March 25, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the Compensation Committee of aTyr’s Board of Directors ...

aTyr Pharma (NASDAQ:LIFE) has filed for a $200M mixed shelf offering. The filing does not necessarily indicate that a sale has begun, or will occur in the future. The company said it will use the proceeds for general corporate purposes. The offering can include common stock, preferred st...

aTyr Pharma, Inc. (LIFE) Q4 2021 Earnings Conference Call March 14, 2022 17:00 ET Company Participants Ashlee Dunston - Director, Investor Relations and Corporate Communications Sanjay Shukla - President and Chief Executive Officer Jill Broadfoot - Chief Financial Officer Conference Call Part...

aTyr Pharma press release (NASDAQ:LIFE): Q4 GAAP EPS of -$0.31 misses by $0.03. Cash, cash equivalents and investments as of December 31, 2021, were $107.9M For further details see: aTyr Pharma GAAP EPS of -$0.31 misses by $0.03

FDA End-of-Phase 2 meeting provides development pathway for efzofitimod (ATYR1923) in pulmonary sarcoidosis; planned registrational study to initiate in the third quarter of 2022. Company ended 2021 with $107.9 million in cash, cash equivalents and investments. Company t...

ACHR, AGRO, ALT, ASLE, BRT, COUP, CVGW, DLO, ENZ, FINV, GTLB, HOFV, LIFE, LRFC, MHLD, MTN, NOAH, OTC:NWHUF, OPTT, PEI, SLGG, SMFR, WPRT, YALA For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings after Monday's close